Cipla gets FDA approval for generic version of Novartis’ Durezo
Cipla Limited said that it has secured final approval for its abbreviated new drug application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05% from the US Food ... Read More
Cipla, Dr. Reddy’s, and others to collaborate on Molnupiravir Covid trial
Five Indian pharma companies – Cipla, Dr. Reddy’s Laboratories, Emcure Pharmaceuticals, Sun Pharmaceutical Industries, and Torrent Pharmaceuticals will join forces to undertake a clinical trial ... Read More
Cipla associate Avenue Therapeutics fails to get FDA approval for IV tramadol
Cipla’s step-down associate firm Avenue Therapeutics has failed to get approval from the US Food and Drug Administration (FDA) for IV tramadol as an alternative ... Read More
Cipla partners with MSD to manufacture and distribute Molnupiravir drug to treat Covid-19
Cipla has entered into a non-exclusive licensing agreement with MSD (called Merck in the US and Canada) for the manufacturing and distribution of Molnupiravir (EIDD-2801/MK-4482), ... Read More
Cipla, Stempeutics Research to launch Stempeucel for critical limb ischemia
Cipla announced that its partner Stempeutics Research has secured regulatory approval from the Drug Controller General of India (DCGI) for the launch of Stempeucel, a ... Read More
Cipla gets FDA’s final approval for generic version of Migranal with CGT designation
Cipla has secured final approval for its abbreviated new drug application (ANDA) for Dihydroergotamine Mesylate Nasal Spray 4mg/mL from the US Food and Drug Administration ... Read More